CD Biosynsis offers integrated Bacillus subtilis Strain Development and Screening Services, providing end-to-end solutions for engineering high-performance microbial hosts for industrial biomanufacturing. Leveraging our expertise in synthetic biology, metabolic engineering, and automated high-throughput screening (HTS), we transform wild-type B. subtilis into robust production strains capable of maximizing the yield of target compounds (e.g., proteins, fine chemicals, enzymes). Our platform includes advanced tools like CRISPR-Cas9 genome editing for precise modifications, promoter engineering for optimized gene expression, and rapid strain screening cycles. We specialize in developing stable, high-titer strains customized for your specific fermentation requirements, significantly accelerating your R&D timeline.
Get a QuoteEfficient biomanufacturing hinges on the quality of the microbial host. Developing a superior Bacillus subtilis production strain requires a systematic approach to balance growth rate, pathway flux, and tolerance to industrial conditions. Our services address the bottlenecks in traditional strain development by integrating the power of multiplex gene editing with fast, quantitative screening methods. This Design-Build-Test-Learn (DBTL) cycle allows for the rapid iteration and identification of optimal genetic configurations, ensuring the developed strain is not only high-yielding in the lab but also stable and scalable for industrial fermenters. We handle everything from chassis selection to final strain performance validation.
CRISPR-Cas9 Multiplex Editing
Simultaneous and precise modification of multiple target genes in the Bacillus subtilis genome using optimized CRISPR-Cas9 systems for pathway optimization.
Promoter and RBS Engineering
Rational design and screening of promoter and RBS libraries to achieve optimal, balanced expression of pathway enzymes and increase target flux.
Chassis Host Selection & Detoxification
Selecting the best parent strain and engineering detoxification pathways to improve tolerance to product toxicity, substrates, or harsh industrial conditions.
Automated Liquid Handling
Utilizing robotic systems to screen thousands of mutant strains in miniaturized formats (e.g., 96-well plates) to find the best performers quickly.
Fluorescence-Activated Cell Sorting (FACS)
Implementation of fluorescent biosensors for the direct, high-speed sorting and enrichment of strains with enhanced production phenotypes.
Quantitative Product Analysis
Rapid HPLC, GC-MS, and LC-MS/MS methods for the accurate quantification of target molecules and byproducts during the screening phase.
Adaptive Laboratory Evolution (ALE)
Applying controlled evolutionary pressure to strains to increase fitness, yield, and tolerance under specific industrial fermentation conditions.
Fermentation Media Optimization
Testing and optimization of media components (carbon source, nitrogen source, precursors) to maximize specific productivity during scale-up.
Genetic Stability Testing
Thorough testing of the final strain's stability over multiple generations and passages to ensure reliable performance during large-scale manufacturing.
Our methodology follows the modern Design-Build-Test-Learn (DBTL) cycle for rapid, data-driven strain improvement.
1. Design & Target Identification
2. Build & Genetic Modification
3. Test & High-Throughput Screening
4. Learn & Scale-Up Validation
Computational modeling of the metabolic pathway.
Identification of genetic targets for editing (knockout, knock-in) and optimization (promoters, RBS).
Formulation of the genetic library strategy.
Construction of genetic parts and combinatorial libraries.
Precise CRISPR-Cas9 editing and transformation into the B. subtilis host.
Verification of successful library construction.
Data analysis to inform the next design cycle (Learn).
Final strain validation in a bioreactor environment.
Delivery of the high-titer strain and detailed Strain Performance Report.
Integrated HTS Platform
Automated High-Throughput Screening reduces the screening cycle time by up to 80%, rapidly identifying superior strains.
Multiplex CRISPR-Cas9 Mastery
Expertise in simultaneous editing of multiple genes, essential for optimizing complex metabolic and regulatory pathways.
Data-Driven DBTL Cycle
Utilizes bioinformatics and quantitative analytics at every step to ensure rational and efficient strain design and iteration.
Industrial Scalability Focus
Strains are optimized for stability, high cell density, and performance under relevant industrial fermentation conditions.
"The integration of their CRISPR editing with automated HTS was game-changing. They screened thousands of variants and delivered a strain with triple the yield in just three months."
Dr. Emily Carter, Head of Strain Engineering, Industrial Biotechnology Firm
"We needed a B. subtilis strain tolerant to high salt concentrations. Their Adaptive Laboratory Evolution (ALE) service, followed by genetic verification, produced a highly robust and stable production host."
Mr. Kevin Zheng, Senior Scientist, Food-Grade Additive Company
"Their team successfully performed multiplex editing across seven different gene loci to fine-tune our entire pathway. The final strain showed unparalleled performance and stability in our 50L fermenter tests."
Dr. Wei Li, CEO, Biopharma Manufacturing Startup
"The detailed data from their screening and analytics informed our follow-up research perfectly. This data-driven approach saved us months of trial-and-error in strain optimization."
Professor Alex Rivas, Principal Investigator, Synthetic Biology Research Center
What is the main goal of your strain development service?
The main goal is to engineer a highly stable and productive Bacillus subtilis strain optimized for maximizing the yield (titer) and production rate (productivity) of a specific target compound under industrial conditions.
How does High-Throughput Screening (HTS) accelerate the process?
HTS utilizes automation and miniaturized formats to test thousands of engineered strain variants simultaneously. This rapid testing cycle allows us to quickly identify and advance the highest-performing clones, drastically shortening the R&D timeline.
Can you work with complex pathways requiring multiple gene edits?
Yes, our expertise lies in Multiplex CRISPR-Cas9 Editing, enabling the simultaneous modification of multiple genes (e.g., knocking out byproducts and knocking in heterologous genes) to optimize complex metabolic pathways effectively.
What is the 'Learn' phase of the DBTL cycle?
In the 'Learn' phase, we analyze the quantitative data (yield, flux, stability) from the 'Test' phase to extract design rules and identify new targets. This informs the next iteration of the 'Design' phase, creating a continuous improvement cycle.
Do you perform Adaptive Laboratory Evolution (ALE) as a service?
Yes. ALE is used to enhance strain fitness, stability, and tolerance to specific fermentation conditions (e.g., pH, temperature, product concentration) that cannot be easily addressed by rational editing alone.
How do you ensure the genetic stability of the final strain?
We prioritize chromosomal integration over plasmid-based expression for genetic components. The final strain undergoes rigorous stability testing over hundreds of generations under simulated industrial conditions.
What types of output data are provided with the final strain?
Deliverables include the final high-titer strain, full sequencing verification of all edited sites, quantitative HPLC/GC-MS data on product titer and productivity, and a comprehensive Strain Performance Report.
Can you optimize the strain's tolerance to toxic products or substrates?
Yes. We use combined strategies, including rational gene editing (e.g., enhancing efflux pumps) and ALE, to boost the strain's inherent tolerance to inhibitory compounds often encountered in high-density fermentation.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.